PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246

Trial Profile

PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs APR 246 (Primary) ; Carboplatin; Doxorubicin liposomal
  • Indications Ovarian cancer
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms PISARRO; PiSARRO
  • Sponsors Aprea
  • Most Recent Events

    • 02 Aug 2017 According to Aprea Therapeutics, the results from Phase II study in platinum sensitive HGSOC patients is expect to present in first half of 2018
    • 11 Oct 2016 Results (n=28) of phase Ib portion of the trial, presented at the 41st European Society for Medical Oncology Congress.
    • 10 Oct 2016 According to an Aprea Therapeutics media release, first patient has been enrolled in the phase II part of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top